Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,213,896 papers from all fields of science
Search
Sign In
Create Free Account
PRX 00023
Known as:
PRX-00023
, PRX00023
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
naluzotan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety
S. Brunelli
,
Jessica Aviles
,
K. S. Gannon
,
A. Branscomb
,
S. Shacham
Pharmacology, Biochemistry and Behavior
2009
Corpus ID: 12457859
2008
2008
Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled Trial
K. Rickels
,
S. Mathew
,
+7 authors
J. Reinhard
Journal of Clinical Psychopharmacology
2008
Corpus ID: 40515142
PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the…
Expand
2008
2008
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
S. Mathew
,
A. Garakani
,
J. Reinhard
,
S. Oshana
,
S. Donahue
Clinical Therapeutics
2008
Corpus ID: 10942823
2007
2007
Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
T. Depaulis
2007
Corpus ID: 77032604
: EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist…
Expand
2007
2007
Tolerability, Pharmacokinetics, and Neuroendocrine Effects of PRX‐00023, a Novel 5‐HT1A Agonist, in Healthy Subjects
G. Iyer
,
John F. Reinhard Jr
,
S. Oshana
,
M. Kauffman
,
S. Donahue
Journal of clinical pharmacology
2007
Corpus ID: 30536648
PRX‐00023 is a novel, nonazapirone 5‐HT1A agonist in clinical development for treatment of affective disorders. The objectives of…
Expand
Review
2007
Review
2007
Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
T. de Paulis
Current opinion in investigational drugs
2007
Corpus ID: 35371886
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist…
Expand
Highly Cited
2006
Highly Cited
2006
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
O. Becker
,
D. Dhanoa
,
+10 authors
S. Noiman
Journal of Medicinal Chemistry
2006
Corpus ID: 34340711
We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of…
Expand
2006
2006
PIII‐42
G. Iyer
,
S. Donahue
,
S. Potter
,
C. Wang
,
S. Oshana
,
M. Kauffman
2006
Corpus ID: 76334477
2006
2006
Gateways to clinical trials.
M. Bayes
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2006
Corpus ID: 38511304
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2005
2005
PRX 00023 may reduce symptoms of GAD
2005
Corpus ID: 195160372
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE